JP2010514676A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514676A5
JP2010514676A5 JP2009542940A JP2009542940A JP2010514676A5 JP 2010514676 A5 JP2010514676 A5 JP 2010514676A5 JP 2009542940 A JP2009542940 A JP 2009542940A JP 2009542940 A JP2009542940 A JP 2009542940A JP 2010514676 A5 JP2010514676 A5 JP 2010514676A5
Authority
JP
Japan
Prior art keywords
group
optionally
alkyl
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514676A (ja
JP5406039B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/026190 external-priority patent/WO2008079346A1/en
Publication of JP2010514676A publication Critical patent/JP2010514676A/ja
Publication of JP2010514676A5 publication Critical patent/JP2010514676A5/ja
Application granted granted Critical
Publication of JP5406039B2 publication Critical patent/JP5406039B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542940A 2006-12-21 2007-12-21 タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体 Expired - Fee Related JP5406039B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US87630706P 2006-12-21 2006-12-21
US60/876,307 2006-12-21
US92229107P 2007-04-06 2007-04-06
US60/922,291 2007-04-06
US94770707P 2007-07-03 2007-07-03
US60/947,707 2007-07-03
US98901407P 2007-11-19 2007-11-19
US60/989,014 2007-11-19
PCT/US2007/026190 WO2008079346A1 (en) 2006-12-21 2007-12-21 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013227246A Division JP2014051516A (ja) 2006-12-21 2013-10-31 タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2010514676A JP2010514676A (ja) 2010-05-06
JP2010514676A5 true JP2010514676A5 (cg-RX-API-DMAC10.html) 2011-06-30
JP5406039B2 JP5406039B2 (ja) 2014-02-05

Family

ID=39272205

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009542940A Expired - Fee Related JP5406039B2 (ja) 2006-12-21 2007-12-21 タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
JP2013227246A Pending JP2014051516A (ja) 2006-12-21 2013-10-31 タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013227246A Pending JP2014051516A (ja) 2006-12-21 2013-10-31 タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体

Country Status (13)

Country Link
US (3) US8247421B2 (cg-RX-API-DMAC10.html)
EP (2) EP2815750A1 (cg-RX-API-DMAC10.html)
JP (2) JP5406039B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090091350A (cg-RX-API-DMAC10.html)
CN (1) CN101678022A (cg-RX-API-DMAC10.html)
AR (1) AR064675A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007338754A1 (cg-RX-API-DMAC10.html)
CA (1) CA2673472A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009006700A (cg-RX-API-DMAC10.html)
NO (1) NO20092668L (cg-RX-API-DMAC10.html)
NZ (1) NZ577798A (cg-RX-API-DMAC10.html)
TW (1) TW200838517A (cg-RX-API-DMAC10.html)
WO (1) WO2008079346A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP2008545660A (ja) * 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2008079346A1 (en) * 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
KR20090129488A (ko) 2007-03-22 2009-12-16 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 ｎ-헤테로사이클릭 화합물
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
NZ595723A (en) 2009-03-17 2012-10-26 Daiichi Sankyo Co Ltd Amide derivative
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
PE20120325A1 (es) * 2009-05-19 2012-04-12 Dow Agrosciences Llc Aminopirimidinas sustituidas con arilo como agentes fungicidas
GEP20207129B (en) * 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
AU2011343647A1 (en) * 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2014004543A1 (en) * 2012-06-25 2014-01-03 Mone Zaidi Consulting, Inc. Combination cancer therapy using bisphosphonates and anti-egfr agents
ME03000B (me) * 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
CN106279126B (zh) * 2013-07-16 2019-05-24 杭州普晒医药科技有限公司 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
US10774068B2 (en) * 2015-06-25 2020-09-15 The Scripps Research Institute Composition and methods for inhibiting mammalian sterile 20-like kinase 1
EP3371203B1 (en) * 2015-11-02 2020-02-26 University Of Rochester Bortezomib conjugates and methods using same
EP3383875B1 (en) 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN110372713B (zh) * 2019-08-15 2022-05-17 广州市汉普医药有限公司 一种普拉洛芬的精制纯化方法
AU2020405446A1 (en) * 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
AU2021263383A1 (en) 2020-04-29 2022-11-24 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
AU2022264775A1 (en) * 2021-04-26 2023-11-09 Ohio State Innovation Foundation Lipid nanomaterials and uses thereof
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2025228376A1 (zh) * 2024-04-30 2025-11-06 阿诺医药 (新加坡) 有限公司 Cyclin K降解剂药物及其抗体偶联物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221717A (en) 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
JP2779403B2 (ja) 1988-11-29 1998-07-23 日本バイエルアグロケム株式会社 殺虫性ニトロ化合物
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CZ2001959A3 (cs) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US20030153560A1 (en) * 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
DE60027431T2 (de) 1999-07-02 2007-07-12 Stuart A. Rancho Santa Fe Lipton Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CN1642973A (zh) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
EA200300717A1 (ru) 2000-12-22 2003-12-25 Уайт Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
DE60201829T2 (de) 2001-03-14 2005-10-27 Wyeth Azaheterocyclylmethylderivative des 2,3-dihydro-1,4-dioxino(2,3-f)chinolin als antidepressivum
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002085896A1 (en) 2001-04-24 2002-10-31 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
CN1503798A (zh) 2001-04-26 2004-06-09 抗抑郁的氧杂环稠合的－[1,4]苯并二噁烷的氮杂环基甲基衍生物
MXPA03009828A (es) 2001-04-26 2005-03-07 Wyeth Corp Sssri) azaheterociclilmetil derivados de 7,8-dihidro-3h-t,9-dioxa-1,3-diazaciclopenta[a]naftaleno como agentes antidepresivos.
ATE334989T1 (de) 2001-04-26 2006-08-15 Wyeth Corp Antidepressive azaheterocyclylmethyl-derivate von 2,3-dihydro-1,4-dioxino 2,3-föchinoxalin
CN1256337C (zh) 2001-04-30 2006-05-17 惠氏公司 抗抑郁的7,8－二氢－1,6,9－三氧杂－3－氮杂－环戊二烯并[a]萘的氮杂环基甲基衍生物
CA2447150A1 (en) 2001-05-17 2002-11-21 Wyeth Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline
CA2450769A1 (en) * 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US20040236110A1 (en) * 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003216660A1 (en) * 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
MXPA05001367A (es) 2002-08-02 2005-04-28 Vertex Pharma Composiciones de pirazol utiles como inhibidores de gsk-3.
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US7262200B2 (en) * 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004043936A1 (ja) * 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Ｐｌｋ阻害剤
DE50307267D1 (de) 2003-02-26 2007-06-21 Boehringer Ingelheim Pharma Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US7432375B2 (en) 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
US7514448B2 (en) 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
TW200616632A (en) 2004-06-17 2006-06-01 Plexxikon Inc Compounds modulating c-kit activity and uses therefor
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
NZ553267A (en) * 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
CA2577947A1 (en) * 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Novel substituted imidazole derivative
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2005309566A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
MX2007007330A (es) * 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
US8633205B2 (en) 2005-02-03 2014-01-21 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TW200800921A (en) 2005-09-19 2008-01-01 Astrazeneca Ab Novel compounds
CN101801971A (zh) 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
NZ592968A (en) 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
WO2007095223A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
JP2009532475A (ja) * 2006-04-05 2009-09-10 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼの阻害剤として有用なデアザプリン
ES2431466T3 (es) * 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
WO2008079346A1 (en) * 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CN101663295B (zh) 2007-03-09 2014-11-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶类化合物
JP5393489B2 (ja) 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
US8173635B2 (en) * 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases

Similar Documents

Publication Publication Date Title
EP1827441B1 (en) Combinations for the treatment of diseases involving cell proliferation
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
AU2016357413B2 (en) Modulators of chemokine receptors
JP2009515852A (ja) Ｅｇｆｒ／ｈｅｒ２インヒビターを含む癌の組み合わせ治療
JP2008509948A5 (cg-RX-API-DMAC10.html)
JP2009515852A5 (cg-RX-API-DMAC10.html)
JP2010503717A5 (cg-RX-API-DMAC10.html)
RU2009128046A (ru) Производные 5-циано-4-(пирроло)(2,3b)пиридин-3-ил)пиримидина в качестве ингибиторов протеинкиназы
ES2368245T3 (es) Combinaciones para el tratamiento de enfermedades que implican una proliferación celular.
CA3005656C (en) Oxoisoindolinyl compounds as modulators of chemokine receptors
AU2011226830A1 (en) Combinations for the treatment of diseases involving cell proliferation
BR112018009880B1 (pt) Compostos e composições farmacêuticas moduladores dos receptores de quimiocina e seus usos
HK1262134A1 (en) Modulators of chemokine receptors
HK1262134B (en) Modulators of chemokine receptors